精神心理指南

订阅

MedSci主页 / 所有栏目 / 精神心理指南

痴呆及阿尔茨海默病进展要点简析

2022-07-26 四川大学华西医院 现代临床医学

老年痴呆症阿尔兹海默病要点解读

随着全球人口老龄化进程的加深，痴呆所引发的卫生、经济、社会方面的问题显著。当下全球罹受COVID-19疫情的影响，痴呆诊治面临更大困境。本文对痴呆及阿尔茨海默病的研究进展进行综述，旨在提升大众对痴呆的

中文标题：

痴呆及阿尔茨海默病进展要点简析

发布机构：

四川大学华西医院

发布日期：

2022-07-26

简要介绍：

随着全球人口老龄化进程的加深，痴呆所引发的卫生、经济、社会方面的问题显著。当下全球罹受COVID-19疫情的影响，痴呆诊治面临更大困境。本文对痴呆及阿尔茨海默病的研究进展进行综述，旨在提升大众对痴呆的总体认识。

相关资料下载：
[AttachmentFileName(sort=1, fileName=痴呆及阿尔茨海默病进展要点简析_孙雪莲.pdf)] GetToolGuiderByIdResponse(projectId=1, id=486641c0025a643d, title=痴呆及阿尔茨海默病进展要点简析, enTitle=, guiderFrom=现代临床医学, authorId=0, author=, summary=随着全球人口老龄化进程的加深，痴呆所引发的卫生、经济、社会方面的问题显著。当下全球罹受COVID-19疫情的影响，痴呆诊治面临更大困境。本文对痴呆及阿尔茨海默病的研究进展进行综述，旨在提升大众对痴呆的, cover=https://img.medsci.cn/Random/black-medical-stethoscope-PNNGEKA.jpg, journalId=0, articlesId=null, associationId=2629, associationName=四川大学华西医院, associationIntro=四川大学华西医院, copyright=0, guiderPublishedTime=Tue Jul 26 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">随着全球人口老龄化进程的加深，痴呆所引发的卫生、经济、社会方面的问题显著。当下全球罹受COVID-19疫情的影响，痴呆诊治面临更大困境。本文对痴呆及阿尔茨海默病的研究进展进行综述，旨在提升大众对痴呆的总体认识。</span></p>, tagList=[TagDto(tagId=950, tagName=老年痴呆症), TagDto(tagId=5786, tagName=阿尔兹海默病), TagDto(tagId=440350, tagName=要点解读)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=5786, articleKeyword=阿尔兹海默病, articleKeywordNum=6, guiderKeywordId=5786, guiderKeyword=阿尔兹海默病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=128254, appHits=220, showAppHits=0, pcHits=3370, showPcHits=128032, likes=1, shares=29, comments=4, approvalStatus=1, publishedTime=Thu Jul 28 10:30:00 CST 2022, publishedTimeString=2022-07-26, pcVisible=1, appVisible=1, editorId=0, editor=lixiang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=lixiang, createdTime=Tue Jul 26 11:18:58 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 22:30:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=痴呆及阿尔茨海默病进展要点简析_孙雪莲.pdf)])
痴呆及阿尔茨海默病进展要点简析_孙雪莲.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1240964, encodeId=58c6124096448, content=在范德萨发地方, beContent=null, objectType=guider, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=81955477682, createdName=ms4000000599238185, createdTime=Thu Aug 25 16:32:34 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240069, encodeId=8ce4124006936, content=下载了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Sun Aug 21 08:53:32 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236379, encodeId=380012363e929, content=有用，下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b48259343, createdName=ms8000001390208262, createdTime=Wed Aug 03 16:00:56 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235891, encodeId=29a01235891f6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Mon Aug 01 10:19:34 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-25 ms4000000599238185

    在范德萨发地方

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1240964, encodeId=58c6124096448, content=在范德萨发地方, beContent=null, objectType=guider, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=81955477682, createdName=ms4000000599238185, createdTime=Thu Aug 25 16:32:34 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240069, encodeId=8ce4124006936, content=下载了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Sun Aug 21 08:53:32 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236379, encodeId=380012363e929, content=有用，下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b48259343, createdName=ms8000001390208262, createdTime=Wed Aug 03 16:00:56 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235891, encodeId=29a01235891f6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Mon Aug 01 10:19:34 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-21 ms5000001410456216

    下载了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1240964, encodeId=58c6124096448, content=在范德萨发地方, beContent=null, objectType=guider, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=81955477682, createdName=ms4000000599238185, createdTime=Thu Aug 25 16:32:34 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240069, encodeId=8ce4124006936, content=下载了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Sun Aug 21 08:53:32 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236379, encodeId=380012363e929, content=有用，下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b48259343, createdName=ms8000001390208262, createdTime=Wed Aug 03 16:00:56 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235891, encodeId=29a01235891f6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Mon Aug 01 10:19:34 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-03 ms8000001390208262

    有用，下载学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1240964, encodeId=58c6124096448, content=在范德萨发地方, beContent=null, objectType=guider, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=81955477682, createdName=ms4000000599238185, createdTime=Thu Aug 25 16:32:34 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240069, encodeId=8ce4124006936, content=下载了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Sun Aug 21 08:53:32 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236379, encodeId=380012363e929, content=有用，下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0b48259343, createdName=ms8000001390208262, createdTime=Wed Aug 03 16:00:56 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235891, encodeId=29a01235891f6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=ms5000001410456216, createdTime=Mon Aug 01 10:19:34 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-01 ms5000001410456216

    学习了

    0

相关指南

提高阿尔茨海默病和相关痴呆的动物实验设计和可重复性指南：对基金提供者和研究者

阿尔茨海默病协会(AA,Alzheimer&#039;s Association) · 2016-10-25

拓展阅读

Science发布，阿尔兹海默病发病机制领域的奠基性研究被锤造假

美国范德堡大学的神经学家 Matthew Schrag 经历数月调查竟发现，包括这篇 Nature 文章在内，涉及 Aβ*56 的论文中都存在可能有问题的图像，数量高达 10 篇！

Mol Psychiatry：阿尔茨海默病风险基因 BIN1 调节人诱导的谷氨酸能神经元中的活性依赖性基因表达

神经元特性的 BIN1 依赖性改变可能有助于 AD 的病理生理学，并且应考虑使用低剂量临床批准的钙阻滞剂治疗作为减缓疾病发作和进展的一种选择。

Mol. Psychiatry：基于脑脊液生物标志物的不同炎症特征与大脑结构和认知的保留或减弱有关

虽然较高水平的 TAM 受体 （sTyro/sAXL） 或 sTREM2 可能反映了对与吞噬细胞清除相关的变性的保护性神经胶质反应，但其他标志物可能更能反映对大脑完整性产生不利影响的促炎状态。

Neurology：轻度神经心理缺陷与主观认知功能减退的相关性

MNPD是认知正常的因SCD而寻求医疗咨询的AD相关临床进展的危险因素。对MNPD的评估可能有助于个体临床预测和临床试验中的AD风险分层。即使在没有MNPD的情况下，SCD仍然是未来认知下降的危险因素

第99届美国神经病理学家协会年会|摘要汇报：基质金属蛋白酶或可助于AD诊断

MMPs源自血管，出现在CSF中，MMP1是动脉平滑肌和周细胞完整性的有用标志物，MMP10将为VCID和AD的组织病理学中的血管周围炎症和神经元损伤提供信息。

NRR：维拉帕米在阿尔茨海默病治疗中改善认知能力的获益已得到进一步证实

阿尔茨海默病（AD）严重威胁人类健康，是目前仍在上升的唯一主要死因，其总体成本已超过癌症和心脏病的总和，已发展成为全球性危机。

2022 欧洲共识：MCI和轻度痴呆初级阶段的诊断和治疗

意大利阿尔兹海默病专家组 · 2022-10-09

阿尔茨海默病相关指南及专家共识解读——全周期康复新视角

复旦大学附属华山医院康复医学科 · 2021-01-01

意大利专家意见和实用指南：在使用淀粉样蛋白降解剂治疗痴呆的时代重新定义痴呆症的护理

暂未更新 · 2023-03-09